Drug Type Autologous CAR-T |
Synonyms CAR19 T cells carrying cytoplasmic activated PD1 |
Target |
Action modulators, inhibitors |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), PD-1 inhibitors(Programmed cell death protein 1 inhibitors), T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Phase 1 | China | 12 Apr 2018 | |
B-Cell Lymphoma | Phase 1 | China | 12 Apr 2018 | |
Recurrent Non-Hodgkin Lymphoma | Phase 1 | China | 12 Apr 2018 | |
Recurrent Non-Hodgkin Lymphoma | Phase 1 | China | 12 Apr 2018 |